David R. Guyer, M.D.
Chief Executive Officer
Following a successful career in academic medicine as Professor and Chairman of the Department of Ophthalmology at New York University School of Medicine, Dr. Guyer co-founded and served as CEO and Director at Eyetech Pharmaceuticals, Inc., where he led the company through private, public and corporate financings over $400 million, and oversaw the rapid development and successful commercialization of Macugen® (pegaptanib sodium), the first FDA-approved anti-VEGF pharmacological treatment for wet AMD. Under his leadership, Eyetech reached a peak market capitalization of approximately $2 billion.
Dr. Guyer received his Bachelor of Science (B.S.) degree from Yale College summa cum laude and his medical degree (M.D.) from Johns Hopkins Medical School. He completed his ophthalmology residency at Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.
Glenn P. Sblendorio, M.B.A.
Executive Vice President, Chief Operating Officer and Chief Financial Officer
Previously, Mr. Sblendorio was the Chief Executive Officer and Managing Director of MPM Capital Advisors, LLC, an investment bank specializing in healthcare related transactions. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions, including Vice President, Finance of Roche Molecular Systems and Head of Finance-Controller for Amgen/Roche Europe. Mr. Sblendorio currently serves on the board of directors of Amicus Therapeutics and Intercept Pharmaceuticals.
Mr. Sblendorio received his Bachelor of Business Administration (B.B.A,) degree from Pace University and a Master of Business Administration (M.B.A.) degree from Fairleigh Dickinson University, and he is a graduate of the Harvard Business School Advanced Management Program.
Carmen A. Puliafito, M.D., M.B.A.
Chief of Strategic Development
Dr. Puliafito is recognized worldwide for his innovative advances such as the co-invention of optical coherence tomography (OCT), a revolutionary technology for the management of macular diseases. He also pioneered basic science research in excimer laser photoablation and optical breakdown and photodisruption. Dr. Puliafito has also been at the forefront of clinical innovation, including the introduction of Avastin® for the treatment of retinal disorders. Dr. Puliafito is on leave from his position as Professor of Ophthalmology and Health Management at the USC Roski Eye Institute.
Dr. Puliafito received his medical degree (M.D.) from Harvard Medical School and a Master of Business Administration (M.B.A.) degree from the Wharton School of the University of Pennsylvania.
Senior Vice President and Chief Commercial Officer
Mr. Bjarke brings a wealth of commercial experience in the retina and ophthalmology market, having previously served as Vice President of Sales and Marketing at Eyetech Pharmaceuticals and playing an important role in bringing the first anti-VEGF product to market for the treatment of wet AMD. In addition, Mr. Bjarke held several roles with increased responsibilities at Pharmacia and Watson Pharmaceuticals. He managed multiple U.S. and global brands and successfully managed several major launches including XALATAN®, which was the world’s number one brand of glaucoma medication (based on market share) and the first ophthalmic medicine to achieve blockbuster status.
Mr. Bjarke holds a Bachelor of Applied Science (B.A. Sc.) degree in Business Administration and Economics from Uppsala University, Sweden.
Evelyn Harrison, M.B.A.
Chief Clinical Operations Officer
Prior to joining Ophthotech, Ms. Harrison was with Eyetech Pharmaceuticals, Inc., where she held the management positions of Vice President and Senior Vice President of Clinical Research and Development. During her stint at this company, she played a key role in the development and approval of Macugen® (pegaptanib sodium) for the treatment of wet age-related macular degeneration.
Ms. Harrison’s professional career began in clinical research at a major New York City teaching hospital. She then moved to Hoffmann-La Roche Inc., where she was Director of Clinical Operations, responsible for the development and implementation of strategic programs for Roche’s oncology franchise.
Ms. Harrison has worked on all phases of global clinical trials and has extensive experience in multiple therapeutic areas such as bone marrow transplantation, organ transplantation, oncology and virology.
Ms. Harrison holds a B.A. degree in Biology from Hofstra University and a Master of Business Administration (M.B.A.) degree from Manhattan College.
Kourous A. Rezaei, M.D.
Senior Vice President, Medical Strategy
Dr. Rezaei received his medical degree from the University of Cologne in Germany. He served as chief resident while completing his residency at the University of Chicago. Dr. Rezaei completed his vitreoretinal surgery fellowship at the Kresge Eye Institute in Detroit.
Thomas A. Ciulla, M.D., M.B.A.
Vice President, Clinical Strategy
Senior Vice President, Technical Operations
Keith Westby, M.B.A.
Senior Vice President, Development Operations
Prior to joining Ophthotech, Mr. Westby worked at Pharmasset, Inc., as Director, Project and Alliance Management, accountable for developing and implementing strategy across manufacturing, research and development, preclinical, clinical, regulatory, and finance for both internal and partnered projects. He also served in positions of increasing responsibility at Eyetech Pharmaceuticals, most recently as Director, Alliance & Project Management, leading multifunctional project teams in the NDA filing and marketing approval of Macugen® (a pegylated oligonucleotide). Previously Mr. Westby worked at Tunnell Consulting, where he was a Senior Consultant in the firm’s Life Sciences practice focused on manufacturing operations and process improvement.
Mr. Westby holds a Bachelor of Science (B.S.) degree in Applied Physics from the State University of New York, College at Geneseo, a Master of Science (M.S.) degree in Engineering Management from Drexel University, and a Master of Business Administration (M.B.A.) degree from Columbia Business School.
Senior Vice President and General Counsel
Before joining OSI, Ms. Wood was a partner at the New York firm of Squadron, Ellenoff, Plesent & Sheinfeld (now part of Hogan Lovells), focusing on mergers and acquisitions, biotechnology, licensing, securities and venture capital matters. While at Squadron Ellenoff, she also worked on transactions for some of the earliest biotech companies, representing an early biotech venture capitalist and angel investor. Ms. Wood received her law degree from Columbia Law School and has a Bachelor of Arts (B.A.) degree in Economics and Classics from Connecticut College.